Healthy Pregnant Women
Conditions
Brief summary
The aim of this study is to collect information how adding a soft gel preparation of micronutrients such as vitamins, dietary minerals plus omega-3 fatty acid (docosahexaenoic acid, DHA) to the diet of pregnant women during the 2nd and 3rd trimesters of pregnancy effects the nutritional state of the mother and infants at delivery.
Interventions
DIETARY_SUPPLEMENTElevit Pregnancy 2nd & 3rd Trimester
Once daily micronutrient plus DHA supplementation (Multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules)
OTHERNon-Supplement
Control study group of pregnant women non-supplemented with multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules
Sponsors
Bayer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 42 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy pregnant Caucasian women aged 18 to 42 years (inclusive) in their 1st - 2nd trimester (gestational age (GA) week 11-14 at screening); * Hemoglobin (Hg) \> 105g/L; * Inconspicuous fetal anomaly screening; * Normal ultrasound examination (Ultra Sonography (USG)); * Singleton pregnancy; * Taking at least 400 mcg folate per day; * Seronegative for Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis C at screening; * Pregnant women who, in the opinion of the Investigator, are willing and able to participate in all scheduled visits, to adhere to the supplementation plan, to laboratory tests and to all other study related procedures according to the clinical protocol; * Pregnant women providing a personally signed and dated given informed consent to participate in the study and to adhere to all study procedures indicating that they have been informed of all pertinent aspects of the trial and that they understood and accepted these, prior to admission to the study.
Exclusion criteria
* Physical (including vital signs e.g. blood pressure and pulse rate), hematological and clinical-chemical parameters deviating from normal and with clinical relevance; * Any infection (acute or chronic) at screening and baseline; * Any current metabolic diseases (e.g. diabetes, hypothyroidism); * Less than 12 months from previous delivery; * Any history or current diseases, which are associated with malabsorption, or other severe diseases of the gastrointestinal tract (e.g. chronic inflammatory bowel disease, iron accumulation, iron utilization disorders); Any history or current neurological, cardiac, endocrine or bleeding disorders; * Specific diets (e.g. vegan vegetarian, celiac, lactose free); * Body mass index (BMI) \< 18 or \>30 kg/m2; * Pregnant women already taking DHA/multivitamin supplements (except folate or iron); * Diagnosed or suspected malignant or premalignant disease; * Current clinically significant depression; * Current intake of pharmaceuticals or dietary supplements which may interact with any of the ingredients of the trial treatment (i.e. fluoroquinolones, bisphosphonates, levodopa, levothyroxine, penicillamine, antibiotics containing tetracycline or trietine); * History of or current diseases where vitamin, mineral, trace element or DHA supplementation might be not recommended /contraindicated \[such as sickle cell anemia, copper metabolism disorders (Wilson's disease), renal disease, nephrolithiasis, urolithiasis, hypercalcemia, hypercalciuria, hepatobiliary diseases, existing hypervitaminosis, iron metabolism disorders, hypermagnesemia\]; * Severe Hyperemesis gravidarum; * Previous adverse birth outcomes (e.g. small for gestational age, low birth weight, premature birth, stillbirth, more than two consecutive spontaneous abortions); * Previous adverse pregnancy outcomes (e.g. gestational diabetes); * Diagnosed congenital abnormalities in current or previous pregnancy; * Known carrier or affected with a genetic disease or condition (e.g. mutation carrier for autosomal recessive diseases); * History of or current abuse of drugs, alcohol or other substances; * Current smokers and women who smoked during current pregnancy; * Any history of hypersensitivity or known allergy to any of the ingredients of the study supplement.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline: Blood RBC DHA/wt% TFA | Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36 | In order to assess the beneficial effects of supplementation with micronutrients and DHA (docosahexaenoic acid) during 2nd and 3rd trimesters of pregnancy, the red blood cell (RBC) DHA weight percent of total fatty acids (DHA wt% TFA) will be measured compared to baseline as primary maternal variable. Gestational age is a measure of the age of a pregnancy which is taken from the beginning of the woman's last menstrual period (LMP), or the corresponding age of the gestation as estimated by a more accurate method if available. Such methods include adding 14 days to a known duration since fertilization (as is possible in in vitro fertilization), or by obstetric ultrasonography. The popularity of using such a definition of gestational age is that menstrual periods are essentially always noticed, while there is usually a lack of a convenient way to discern when fertilization occurred. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline: Blood 8-Isoprostane concentration % | Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36 | — |
| Infant sex | At delivery | — |
| Infant gestational age | At delivery | — |
| Change from baseline: Blood RBC EPA/wt% TFA | Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36 | Red blood cell (RBC) EPA (eicosapentaenoic acid) weight percent of total fatty acids (DHA wt% TFA). |
| Change from baseline: Blood RBC DHA/TFA ratio % | Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36 | — |
| Blood, cord blood and placental DHA/TFA ratio % | At delivery | Sample evaluations in a subset of women undergoing Caesarean section. |
| Change from baseline: Blood RBC Omega 3 index in RBC | Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36 | The omega-3 index reflects the content of EPA plus DHA in erythrocyte membranes expressed as a percentage of total erythrocyte fatty acids. |
| Change from baseline: Blood 25-hydroxyvitamin D concentration % | Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36 | — |
| Change from baseline: Blood Glutathione (GSH)/oxidized Glutathione (GSSG) ratio % | Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36 | Glutathione exists in reduced (GSH) and oxidized (GSSG) states. Reduced glutathione is the most abundant antioxidant in aerobic cells and participates in the detoxification of lipid hydroperoxides and hydrogen peroxide exerted by glutathione peroxidases. When cells are exposes to increased oxidative stress levels, GSSG accumulates and the GSH/GSSG ratio decreases. |
| Change from baseline: Blood Reactive oxygen metabolites (ROMs) concentrations % | Baseline: Screening at gestational age (GA) week 11 to 13 and at GA week 24 to 26 and week 34 to 36 | — |
| Infant head circumference | At delivery | — |
| Infant weight measurements | At delivery | — |
| Infant length measurements | At delivery | — |
| Infant ponderal index | At delivery | — |
| Infant skinfold thickness | At delivery | Triplicate measurements: triceps, biceps, suprailiac, and subscapular on left side with standard skinfold caliper operated with constant pressure of 10 g/mm2) |
| Infant Apgar score | At delivery | — |
| Umbilical cord blood gas analysis | At delivery | Cord blood sample evaluations in a subset of women undergoing Caesarean section. |
| Umbilical cord blood pH analysis | At delivery | Cord blood sample evaluations in a subset of women undergoing Caesarean section. |
| Cord blood metabolomic analysis | At delivery | Cord blood sample evaluations in a subset of women undergoing Caesarean section. |
| Placental weight | At delivery | Placenta tissue sample evaluation in a subset of women undergoing caesarean section. Placental efficiency will be estimated through the feto/placental weight (F/P) ratio, calculated as birth weight divided by the placental weight. |
| Placental biometric parameters | At delivery | Placenta tissue sample evaluation in a subset of women undergoing caesarean section. i.e. larger (D) and smaller (d) diameters of the chorionic elliptical disc, feto/placental weight (F/P ratio) |
| Blood, cord blood and placental RBC DHA/wt% TFA | At delivery | Sample evaluations in a subset of women undergoing Caesarean section. |
| Blood, cord blood and placental RBC EPA wt% TFA | At delivery | Sample evaluations in a subset of women undergoing Caesarean section. |
| Blood, cord blood and placental RBC Omega 3 index | At delivery | Sample evaluations in a subset of women undergoing Caesarean section. |
| Mitochondrial DNA content evaluation in placental tissue and isolated trophoblast cells | At delivery | mtDNA is a well-accepted molecular marker to assess mitochondria content. Sample evaluations in a subset of women undergoing Caesarean section. |
| IL-6 (Interleukin 6), IL-10 (Interleukin 10) and TNF-α (Tumor Necrosis Factor Alpha) in placental tissue and isolated trophoblast cells | At delivery | These genes are constitutively expressed in human placenta and are a reliable marker of inflammation. Sample evaluations in a subset of women undergoing Caesarean section. |
| Placental tissue metabolomic analysis | At delivery | Sample evaluations in a subset of women undergoing Caesarean section. The rationale for conducting metabolomic analysis is to understand if multi-micronutrient supplement (MMS) supplementation during the second and third trimester of pregnancy influences maternal and infant gestational outcomes (e.g. oxidative stress, placental function). |
| Blood, cord blood and placental 8-isoprostane | At delivery | Sample evaluations in a subset of women undergoing Caesarean section. |
| Blood, cord blood and placental reactive oxygen metabolites (ROMs) concentrations % | At delivery | Sample evaluations in a subset of women undergoing Caesarean section. |
| Number of Adverse Events (AEs) | Within 7 days after Delivery | — |
| Severity of AEs | Within 7 days after Delivery | — |
| AE relationship to the investigational product | Within 7 days after Delivery | — |
| Infant bone density | Up to 10 days after delivery | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| Maternal Food Frequency Questionnaire FFQ | Up to GA week 34-36 | Focus on foods providing DHA |
Countries
Italy
Outcome results
None listed